TwinStrand Biosciences Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 113

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $50M

  • Investors
  • 11

TwinStrand Biosciences General Information

Description

Developer of a DNA sequencing therapy designed to identify ultra-low frequency genomic variants that are undetectable by conventional methods. The company's therapy offers highly sensitive and specific duplex sequencing technology offers data that can inform critical decisions in clinical medicine, public health and other fields of science on a faster timescale, enabling researchers with clearer insights in applications ranging from residual cancer detection to genetic toxicology.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 3131 Elliott Avenue
  • Suite 750
  • Seattle, WA 98121
  • United States
+1 (877) 000-0000

TwinStrand Biosciences Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TwinStrand Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 30-Apr-2021 $50M 000.00 00000 Completed Generating Revenue
7. Grant 15-Jul-2019 00000 000.00 Completed Generating Revenue
6. Debt - PPP 15-Apr-2020 00000 000.00 Completed Generating Revenue
5. Grant 01-Jan-2020 00.000 000.00 Completed Generating Revenue
4. Early Stage VC (Series A2) 30-Dec-2019 000.00 000.00 000.00 Completed Generating Revenue
3. Grant 01-Jan-2019 00.00 00.00 Completed Generating Revenue
2. Grant 01-Jan-2018 $2.3M $6.1M Completed Generating Revenue
1. Seed Round 13-Sep-2017 $6.1M $6.1M Completed Generating Revenue
To view TwinStrand Biosciences’s complete valuation and funding history, request access »

TwinStrand Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-2 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series A-1 1,665,992 $0.000100 6% $2.58 $2.58 1x $2.58 6.05%
Seed 4,365,624 $0.000100 6% $1.52 $1.52 1x $1.52 15.85%
To view TwinStrand Biosciences’s complete cap table history, request access »

TwinStrand Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a DNA sequencing therapy designed to identify ultra-low frequency genomic variants that are undetectable by
Biotechnology
Seattle, WA
113 As of 2022
000.00
0000 0000-00-00
00000000000 000.00

000000

d do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostr
0000000000000
Seattle, WA
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

000000

lum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa q
0000000000000
Providence, RI
00 As of 0000
0000
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TwinStrand Biosciences Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Stratos Genomics Formerly VC-backed Seattle, WA 00 000.00 000000&0 000.00
000000 Venture Capital-Backed Providence, RI 00 0000 00000000000 0000
000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000000 00000000 Accelerator/Incubator Backed Ebersberg, Germany 00 000000000000
You’re viewing 5 of 28 competitors. Get the full list »

TwinStrand Biosciences Patents

TwinStrand Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020321991-A1 Methods and reagents for nucleic acid sequencing and associated applications Pending 01-Aug-2019 0000000000
US-20220220543-A1 Methods and reagents for nucleic acid sequencing and associated applications Pending 01-Aug-2019 0000000000
CA-3146435-A1 Methods and reagents for nucleic acid sequencing and associated applications Pending 01-Aug-2019 0000000000
EP-4007818-A1 Methods and reagents for nucleic acid sequencing and associated applications Pending 01-Aug-2019 0000000000
US-20220119876-A1 Methods and reagents for efficient genotyping of large numbers of samples via pooling Pending 16-Oct-2018 C12Q1/6858
To view TwinStrand Biosciences’s complete patent history, request access »

TwinStrand Biosciences Executive Team (8)

Name Title Board Seat Contact Info
Elena Cant Chief Operating Officer
Jesse Salk Ph.D Co-Founder, Chief Executive Officer, Chief Scientific Officer & Board Member
Dionne Gordon Financial Controller
Goran Pljevaljcic Ph.D Chief Commercial Officer
Louisa Helms Competitive Analyst
You’re viewing 5 of 8 executive team members. Get the full list »

TwinStrand Biosciences Board Members (12)

Name Representing Role Since
Chad Waite Jr. The W Fund Chairman 000 0000
Jesse Salk Ph.D TwinStrand Biosciences Co-Founder, Chief Executive Officer, Chief Scientific Officer & Board Member 000 0000
Michael Pellini MD Section 32 Board Member 000 0000
Sivaramakichenane Somasegar Madrona Venture Group Board Member 000 0000
Stephen Dow Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

TwinStrand Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TwinStrand Biosciences Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Janus Henderson Investors Asset Manager Minority 000 0000 000000 0
Section 32 Venture Capital Minority 000 0000 000000 0
Soleus Capital PE/Buyout Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Madrona Venture Group Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »